Alector, Inc.

ALEC Healthcare Biotechnology

Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.

1.84 0.07 −3.66%
Market cap
$213.3M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
1/9
Altman Z
−5.15
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — 1 3 5 3 1 2 1
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— — — 2.08 1.62 2.17 0.32 (0.68) (2.20) (5.15)
P/S ratio
7.67 7.67 7.67 50.13 55.76 8.02 5.62 6.89 1.82 7.64
Altman Z″-Score (non-manufacturers)
— 4.05 3.37 1.97 0.60 3.43 2.09 (0.98) (3.26) (9.85)
P/FCF ratio
1.69 1.69 1.69 0.00 0.00 5.62 0.00 0.00 0.00 0.00
Beneish M-Score
— — — — — — (3.91) — — —
P/Operating CF
(12.03) (12.03) (12.03) (36.90) (24.69) (33.71) (15.34) (14.52) (3.32) (3.85)
P/B ratio
0.00 0.00 0.00 5.46 4.40 5.52 3.50 4.99 1.44 5.24
Price to Tangible BV
0.00 0.00 0.00 5.46 4.40 5.52 3.50 4.99 1.44 5.24
EV/Sales
(2.82) (2.82) (2.82) 35.75 38.60 4.70 0.61 1.65 (2.12) (4.07)
EV/EBITDA
1.39 1.39 1.39 0.00 0.00 0.00 0.00 0.00 1.42 0.56
EV/Operating CF
(0.61) (0.61) (0.61) (7.64) (4.88) 3.26 (3.98) (0.87) 0.93 0.47
EV/FCF
(0.62) (0.62) (0.62) (6.62) (4.74) 3.29 (3.31) (0.86) 0.92 0.47
Quick Ratio
33.81 8.49 6.06 5.70 6.07 5.32 7.63 3.08 3.31 3.68
Current Ratio
33.90 8.50 6.11 5.77 6.19 5.37 7.74 3.18 3.40 3.83
Net Debt/EBITDA
3.40 1.01 5.16 2.80 1.93 25.52 5.13 3.47 2.68 1.61
Debt/Assets
0.00% 0.00% 0.00% 11.39% 10.50% 5.84% 5.50% 0.00% 2.00% 3.30%
Debt/Equity
0.00 0.00 0.00 0.25 0.19 0.16 0.20 0.00 0.07 0.32
Asset Turnover
0.00 0.03 0.10 0.06 0.05 0.32 0.17 0.14 0.18 0.06
Operating CF/Net income
0.86 0.55 (2.44) 0.94 0.88 (8.22) 0.15 1.41 1.93 1.29
Capex/Depreciation
(11.19) (1.18) (1.85) (2.74) (0.64) (0.31) (0.56) 0.37 0.23 (0.01)
ROE
39.28% 84.43% 69.93% (216.52%) (82.30%) (12.79%) (51.75%) (74.81%) (91.24%) (181.56%)
ROA
(12.80%) (27.52%) (19.19%) (28.86%) (41.80%) (5.58%) (16.64%) (18.50%) (21.84%) (37.54%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(28.94%) (15.59%) (20.40%) (32.00%) (49.59%) (5.70%) (20.26%) (31.82%) (37.57%) (68.79%)
Average Days of Receivables
191.27 19,568.10 0.00 0.00 0.00 13.03 7.07 0.00 0.00 0.00
Research and Development Expense of Revenue
3,287.02% 800.83% 263.87% 473.76% 743.53% 91.46% 157.48% 197.93% 184.91% 584.77%
Selling, General and Administrative Expense of Revenue
450.48% 174.11% 43.12% 165.39% 281.56% 26.58% 45.68% 58.40% 59.28% 256.53%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
471.88% 143.35% 25.02% 76.73% 144.67% 19.69% 34.54% 44.09% 39.24% 126.67%
Graham Net Nets
0.46 0.46 0.46 0.12 0.17 0.14 0.20 0.12 0.46 0.02
Graham Number
0.00 0.00 29.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(25.40%) (25.40%) (25.40%) (9.87%) (16.13%) (2.28%) (17.69%) (19.40%) (65.08%) (89.10%)
Free Cash Flow Yield
59.15% 59.15% 59.15% (10.77%) (14.60%) 17.78% (3.26%) (27.88%) (126.63%) (114.56%)
Revenue per Share
0.06 0.41 2.45 0.34 0.27 2.58 1.62 1.16 1.04 0.20
Operating CF per Share
(1.81) (1.94) 11.28 (1.61) (2.14) 3.71 (0.25) (2.20) (2.38) (1.79)
Capex per Share
(0.31) (0.09) (0.17) (0.25) (0.06) (0.04) (0.05) (0.03) (0.01) 0.00
Free Cash Flow per Share
(2.13) (2.03) 11.11 (1.86) (2.21) 3.67 (0.30) (2.23) (2.39) (1.79)
Cash per Share
7.09 3.55 25.69 5.72 5.32 9.14 8.64 6.55 4.28 2.49
Shareholders Equity per Share
0.00 2.78 10.01 3.15 3.44 3.74 2.60 1.60 1.31 0.30
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.00 2.78 10.01 3.15 3.44 3.74 2.60 1.60 1.31 0.30
Free Cash Flow
(15.24) (18.57) 125.58 (114.57) (171.77) 295.30 (24.45) (186.54) (231.16) (184.07)
Working Capital
49.68 205.57 245.23 295.47 353.42 610.16 632.63 387.86 299.76 196.95
Capital Expenditures
(2.25) (0.80) (1.88) (15.26) (5.03) (3.25) (4.12) (2.38) (1.25) (0.04)
Net Current Asset Value
51.19 22.37 97.94 130.27 200.79 235.78 153.23 78.14 83.31 3.86
EV/EBIT
1.36 1.36 1.36 0.00 0.00 0.00 0.00 0.00 1.47 0.55
Capex to Sales
5.41 0.21 0.07 0.72 0.24 0.02 0.03 0.02 0.01 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.08 0.24 0.09 0.16 0.26 0.38 0.29 (0.30) (0.32) 0.31
Cash ROIC
(29.98%) (32.07%) 31.12% (19.23%) (23.46%) 27.25% (2.52%) (27.31%) (42.06%) (62.11%)
Accounts Receivable Turnover
0.00 0.04 0.00 0.00 0.00 1.99 26.78 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — — — 0.00 0.00 — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — — — 0.00 0.00 — — —
Average Receivables
100.23 100.23 — — — 103.81 4.99 — — —
Average Payables
1.15 1.15 0.63 0.20 1.64 3.88 4.47 3.98 3.00 1.95
Average Assets
118.03 118.03 272.21 365.14 455.08 651.45 801.15 704.74 545.07 380.77
Average Common Equity
(38.47) (38.47) (74.72) 48.67 231.14 284.13 257.58 174.30 130.48 78.72

Fold the line items

Columns are period end dates